The European Commission has approved obicetrapib, as Ubeslo and as Evlarco (with ezetimibe), for adults with primary hypercholesterolaemia or mixed dyslipidaemia — what the companies call a first-in-class approval for …
The European Commission has approved obicetrapib, as Ubeslo and as Evlarco (with ezetimibe), for adults with primary hypercholesterolaemia or mixed dyslipidaemia — what the companies call a first-in-class approval for …
AbbVie has completed its $10.9 billion acquisition of Apogee Therapeutics, adding zumilokibart — a long-acting interleukin-13 antibody positioned against Dupixent — to its immunology portfolio.
You must be logged in to post a comment.